source
- CellCentric secures $220 million Series D to advance multiple myeloma oral therapyCellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…
- CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodibCellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…